Get notified when CNTA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Securities Litigation (removed) — Securities class action lawsuit alleging false statements about lixivaptan and ZF874 programs was dismissed with prejudice in August 2024 and is no longer active.
Centessa announces $38/share Lilly acquisition; cleminorexton Phase 2 data supports pivotal trials
Filed March 31, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 24, 2025 · ~2 min read
Key Changes
-
high
Eli Lilly agreed to acquire Centessa for $38.00 cash per share plus contingent value rights worth up to $9.00 per share tied to regulatory milestones for cleminorexton and ORX142. Transaction expected to close Q3 2026 pending shareholder approval.
Business: Proposed Lilly acquisition verify on EDGAR → -
high
Cleminorexton Phase 2a data showed statistically significant improvements in wakefulness (>20-minute MWT gain), sleepiness (ESS score improved from 19.6 to 5.1), and 87% cataplexy reduction in narcolepsy type 1, supporting advancement to pivotal trials.
Business: CRYSTAL-1 Phase 2a clinical data verify on EDGAR → -
high
Company raised $269M in equity offerings in 2025 and extended cash runway to mid-2028 from mid-2027, despite R&D spending increasing 15% to $172M driven by orexin program expansion.
MD&A: Cash runway extension verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade CNTA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify